Shares of Gilead Sciences surged 8.7% to ARS 64,650 on October 15, the sharpest single-day jump in months, after the company announced a sweeping oncology collaboration with Vir Biotechnology. Gilead will develop up to three T-cell engager therapies discovered by Vir for solid tumors, in a deal worth up to $1.74 billion in milestones. The market's enthusiasm reflects a broader investor bet: that Gilead can transform itself from an HIV-drug giant into a serious cancer-treatment contender.
The Deal Gives Gilead a Tumor-Targeting Technology It Didn't Have
The technology at the center of this deal — called "masking" — keeps the cancer-killing therapy inactive until it reaches the tumor, aiming to limit the toxic side effects that have historically plagued this class of drug in solid tumors.
Gilead holds exclusive rights to develop and sell whatever comes out of the collaboration, while Vir leads the early lab work.
Vir stands to collect up to $135 million in upfront and near-term payments — $65 million in cash plus a $25 million equity stake priced at a 30% premium — along with up to $45 million in preclinical milestones. For Gilead, it's a pay-as-you-go structure that limits cash exposure until candidates prove themselves.
This Is the Third Major Oncology Move in 2026 Alone
Gilead already completed two significant acquisitions this year: a $7.8 billion buyout of CAR-T cell therapy company Arcellx and a $3.15 billion purchase of antibody-drug conjugate developer Tubulis.
Oncology now appears to be at the center of Gilead's pipeline strategy, designed to complement and eventually offset its reliance on HIV revenues. The Vir collaboration adds a third attack angle — T-cell engagers — to a cancer arsenal that already includes cell therapies and targeted drug-delivery platforms.
The U.S. Stock Moved Less, Suggesting Buenos Aires Amplified the Signal
In U.S. trading, Gilead (GILD) rose 3.1%, with analysts pointing to the Vir collaboration as the most likely catalyst. The GILD.BA rally of 8.7% — nearly triple the U.S. move — likely reflects local market dynamics, lower liquidity, and currency factors. Investors in the Argentine listing should remember that day-to-day swings can overstate or understate the underlying fundamental shift.
Early-Stage Science Still Carries Heavy Risk These drug candidates have not yet entered human trials. The full $1.87 billion in combined payments only flows if all three programs hit development, regulatory, and sales milestones — a process that typically takes a decade. Investors appear to be viewing the deal structure as a measured way to add pipeline upside without a large near-term cash commitment , but the path from lab to pharmacy shelf remains long and uncertain.